Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Show more
Location: 100 Marine Parkway, Redwood City, CA, 94065, United States | Website: https://soleno.life | Industry: Biotechnology | Sector: Healthcare
Market Cap
4.195B
52 Wk Range
$39.41 - $86.67
Previous Close
$83.25
Open
$83.33
Volume
1,335,887
Day Range
$83.13 - $86.79
Enterprise Value
3.958B
Cash
290M
Avg Qtr Burn
-22.33M
Insider Ownership
1.89%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VYKAT XR (diazoxide choline) (DCCR) Details Prader-Willi syndrome | Approved Quarterly sales |